-3.20%
2.60%
-14.53%
-32.72%
-43.19%
-56.03%
11.87%
AI Spotlight on PRTA
Company Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease.
Prothena Corporation plc has a license, development, and commercialization agreement with F.Hoffmann-La Roche Ltd.and Hoffmann-La Roche Inc.
to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies.The company was founded in 2012 and is based in Dublin, Ireland.
Market Data
| Last Price | 14.23 |
| Change Percentage | -3.20% |
| Open | 14.76 |
| Previous Close | 14.7 |
| Market Cap ( Millions) | 766 |
| Volume | 306557 |
| Year High | 31.03 |
| Year Low | 11.7 |
| M A 50 | 14.39 |
| M A 200 | 18.87 |
Financial Ratios
| FCF Yield | -20.23% |
| Dividend Yield | 0.00% |
| ROE | -24.19% |
| Debt / Equity | 2.15% |
| Net Debt / EBIDTA | 319.02% |
| Price To Book | 1.43 |
| Price Earnings Ratio | -5.81 |
| Price To FCF | -4.94 |
| Price To sales | 5.74 |
| EV / EBITDA | -1.62 |
News
- Dec -30 - Prothena Announces Board of Directors Update
- Dec -19 - Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease
- Nov -13 - Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
- Nov -13 - Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
- Nov -11 - Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
- Nov -05 - Prothena to Report Third Quarter 2024 Financial Results on November 12
- Sep -27 - Prothena Announces Leadership Team Updates
- Aug -19 - What Makes Prothena (PRTA) a New Buy Stock
- Aug -09 - Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
- Aug -08 - Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
- Aug -01 - Prothena to Report Second Quarter 2024 Financial Results on August 8
- Jul -25 - Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Jun -24 - Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
- Jun -11 - Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
- Jun -07 - Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
- May -29 - Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
- May -28 - Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
- May -09 - Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
- May -08 - Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
- Apr -25 - Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Collaboration
Expected Growth : 10.43 %
What the company do ?
Prothena Corporation plc collaborates with leading research institutions to advance understanding of neurodegenerative diseases and develop novel therapies.
Why we expect these perspectives ?
Prothena Corporation plc's 10.43% growth is driven by its strategic collaboration, leveraging its neuroscience expertise to develop novel therapies. This partnership enables access to new markets, shared R&D costs, and accelerated product development. Additionally, Prothena's strong pipeline, including its lead candidate prasinezumab, and increasing investment in neurodegenerative disease research contribute to its growth momentum.
Segment n°2 -> License and Intellectual Property
Expected Growth : 10.47 %
What the company do ?
Prothena Corporation plc's license and intellectual property refer to the company's proprietary rights to develop and commercialize its neurodegenerative disease treatments, including patents, trademarks, and copyrights.
Why we expect these perspectives ?
Prothena Corporation plc's 10.47% growth in License and Intellectual Property is driven by increasing demand for its neuroscience-focused therapies, strategic partnerships, and successful patent applications. The company's robust R&D pipeline, coupled with its strong intellectual property portfolio, has enabled it to capitalize on emerging opportunities in the biotech industry.
Prothena Corporation Plc Products
| Product Range | What is it ? |
|---|---|
| Birtamimab | A monoclonal antibody designed to treat amyloid light chain (AL) amyloidosis, a rare and debilitating disease. |
| Prasinezumab | A monoclonal antibody designed to treat Parkinson's disease, a neurodegenerative disorder. |
| PRX004 | A monoclonal antibody designed to treat ATTR amyloidosis, a rare and debilitating disease. |
| PRX012 | A monoclonal antibody designed to treat Alzheimer's disease, a neurodegenerative disorder. |
Prothena Corporation plc's Porter Forces
Threat Of Substitutes
Prothena Corporation plc has a moderate threat of substitutes due to the availability of alternative treatments for neurodegenerative diseases.
Bargaining Power Of Customers
Prothena Corporation plc has a low bargaining power of customers due to the lack of negotiating power of individual patients and the high demand for effective treatments.
Bargaining Power Of Suppliers
Prothena Corporation plc has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment.
Threat Of New Entrants
Prothena Corporation plc has a high threat of new entrants due to the growing interest in neurodegenerative disease research and the availability of funding for biotech startups.
Intensity Of Rivalry
Prothena Corporation plc operates in a highly competitive industry with multiple players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 2.06% |
| Debt Cost | 3.95% |
| Equity Weight | 97.94% |
| Equity Cost | 5.45% |
| WACC | 5.42% |
| Leverage | 2.11% |
Prothena Corporation plc : Quality Control
Prothena Corporation plc passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OXB.L | Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform … |
| PHARM.AS | Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, … |
| EVGN | Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through … |
| ONT.L | Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic … |
| AFMD | Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Oxford Biomedica
A-Score
1-Year Total Return ->
🥈
Evogene
A-Score
1-Year Total Return ->
🥉
Pharming
A-Score
1-Year Total Return ->
4
Prothena
A-Score
1-Year Total Return ->
5
Oxford Nanopore Technologies
A-Score
1-Year Total Return ->
6
